<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093807</url>
  </required_header>
  <id_info>
    <org_study_id>REC 15/2375-IT-CL 0336</org_study_id>
    <nct_id>NCT01093807</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension</brief_title>
  <acronym>FELT</acronym>
  <official_title>Randomized, Parallel Group, Double-blind Trial to Evaluate Different Dose Combinations of Lercanidipine and Enalapril in Comparison With Each Component Administered Alone and With Placebo in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recordati Industria Chimica e Farmaceutica S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recordati Industria Chimica e Farmaceutica S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of various dosage
      combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with
      their respective components and with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in sitting diastolic blood pressure (SDBP)</measure>
    <time_frame>after 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sitting systolic blood pressure (SSBP)</measure>
    <time_frame>after 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters: adverse events, heart rate, laboratory tests physical examination</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">1039</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lercanidipine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lercanidipine 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lercanidipine 10 mg/Enalapril 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lercanidipine 10mg/Enalapril 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lercanidipine 20mg/Enalapril 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lercanidipine 20mg/Enalapril20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily for 10 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine</intervention_name>
    <description>10 mg once daily for 10 weeks</description>
    <arm_group_label>Lercanidipine 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine</intervention_name>
    <description>20 mg once daily for 10 weeks</description>
    <arm_group_label>Lercanidipine 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>10 mg once daily for 10 weeks</description>
    <arm_group_label>Enalapril 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>20 mg once daily for 10 weeks</description>
    <arm_group_label>Enalapril 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine + Enalapril</intervention_name>
    <description>10/10 mg once daily for 10 weeks</description>
    <arm_group_label>Lercanidipine 10 mg/Enalapril 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine + Enalapril</intervention_name>
    <description>10/20 mg once daily for 10 weeks</description>
    <arm_group_label>Lercanidipine 10mg/Enalapril 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine + Enalapril</intervention_name>
    <description>20/10 mg once daily for 10 weeks</description>
    <arm_group_label>Lercanidipine 20mg/Enalapril 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine + Enalapril</intervention_name>
    <description>20/20 mg once daily for 10 weeks</description>
    <arm_group_label>Lercanidipine 20mg/Enalapril20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Office Blood Pressure (BP): Sitting diastolic blood pressure (SDBP)100-109 mmHg
             (inclusive) and sitting systolic blood pressure (SSBP) &lt; 180 mmHg after a 2 week
             placebo run-in period

          -  Home Blood Pressure: diastolic blood pressure (DBP)at home ≥ 85 mmHg in the last week
             of the placebo run-in period

          -  Normal Electrocardiogram (ECG), first degree Atrioventricular block or other changes
             not considered clinically significant

        Exclusion Criteria:

          -  Secondary or severe hypertension

          -  History of cerebro- or cardiovascular complications

          -  Type 1 or Type 2 diabetes on drug treatment

          -  Severe renal or hepatic insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Mancia, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Clinica Medica Ospedale S. Gerardo Università Milano Bicocca Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de la Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>April 28, 2011</last_update_submitted>
  <last_update_submitted_qc>April 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Barbara Bettini - Clinical Project Leader</name_title>
    <organization>Medical Department</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Lercanidipine</keyword>
  <keyword>Calcium antagonist</keyword>
  <keyword>Enalapril</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Lercanidipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

